The estimated Net Worth of Frederick Finnegan is at least $78.8 Thousand dollars as of 19 September 2005. Frederick Finnegan owns over 24,169 units of Cortexyme Inc stock worth over $78,792 and over the last 20 years Frederick sold CRTX stock worth over $0.
Frederick has made over 1 trades of the Cortexyme Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently Frederick exercised 24,169 units of CRTX stock worth $25,377 on 19 September 2005.
The largest trade Frederick's ever made was exercising 24,169 units of Cortexyme Inc stock on 19 September 2005 worth over $25,377. On average, Frederick trades about 6,042 units every 0 days since 2004. As of 19 September 2005 Frederick still owns at least 40,406 units of Cortexyme Inc stock.
You can see the complete history of Frederick Finnegan stock trades at the bottom of the page.
Frederick's mailing address filed with the SEC is C/O CRITICAL THERAPEUTICS, INC., 60 WESTVIEW ROAD, LEXINGTON, MA, 02421.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi, and Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: